Global Next Generation Diabetes Therapy and Drug Delivery Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

Section 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Section 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Section 3 MARKET OVERVIEW

3.1. KEY BENEFITS

3.1.1. Top investment pockets
3.1.2. Top winning strategies

3.2. PATENT ANALYSIS

3.2.1. Patent analysis by year
3.2.2. Patent analysis by region
3.2.3. Patent analysis by product

3.3. GOVERNMENT REGULATIONS

3.3.1. U.S. FDA
3.3.2. Europe CE Mark
3.3.3. Ministry of Health, Labour, and Welfare (MHLW)

3.4. REIMBURSEMENT POLICIES
3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

3.5.1. Smart contact lenses for glucose monitoring
3.5.2. iLet bihormonal bionic pancreas
3.5.3. Glucose nanosensors
3.5.4. Beta cell replacement therapy
3.5.5. Glucose-responsive insulin-producing cells

3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in incidence of diabetes
3.6.1.2. Rise in healthcare expenditure & disposable income
3.6.1.3. Benefits of using next generation diabetes products over conventional products

3.6.2. Restraints

3.6.2.1. Cost restrains
3.6.2.2. Lack of awareness
3.6.2.3. Less variability in products

3.6.3. Opportunities

3.6.3.1. Developing products with fewer side effects at affordable costs
3.6.3.2. High undiagnosed diabetic patient population
3.6.3.3. Tapping potential in developing regions

Section 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INHALABLE INSULIN

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. ORAL INSULIN

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. INSULIN PATCHES

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. CGMS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ARTIFICIAL PANCREAS

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

Section 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14YEARS)

5.2.1. Market size and forecast

5.3. CHILD POPULATION (≤14YEARS)

5.3.1. Market size and forecast

Section 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. TYPE I DIABETES

6.2.1. Market size and forecast

6.3. TYPE II DIABETES

6.3.1. Market size and forecast

Section 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. DIAGNOSTICS/CLINICS

7.2.1. Market size and forecast

7.3. ICUS

7.3.1. Market size and forecast

7.4. HOME HEALTHCARE

7.4.1. Market size and forecast

Section 8 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Canada market size and forecast
8.2.3.3. Mexico market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. Germany market size and forecast
8.3.3.2. UK market size and forecast
8.3.3.3. France market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. South Korea market size and forecast
8.4.3.6. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Saudi Arabia market size and forecast
8.5.3.3. South Africa market size and forecast
8.5.3.4. Rest of LAMEA market size and forecast

Section 9 COMPANY PROFILES

9.1. ABBOTT LABORATORIES

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments

9.2. DEXCOM, INC.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Product portfolio
9.2.4. Business performance
9.2.5. Key strategic moves and developments

9.3. ECHO THERAPEUTICS, INC.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments

9.4. GLYSENS INCORPORATED

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Key strategic moves and developments

9.5. JOHNSON & JOHNSON

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments

9.6. MANNKIND CORPORATION

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Product portfolio
9.6.4. Key strategic moves and developments

9.7. MEDTRONIC PLC.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments

9.8. NOVO NORDISK A/S

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance

9.9. SANOFI

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments

9.10. SENSEONICS HOLDINGS, INC.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Product portfolio
9.10.4. Business performance
9.10.5. Key strategic moves and developments